ARS Pharma reports Q1 revenue $22.7M, neffy net product revenue $17.5M

ARS Pharmaceuticals, Inc.

2026-Q1 EPS reported -$0.61 revenue$22,681,000

Net loss $60.6M ($0.61/share); cash $201M; expects to fund to cash-flow break-even.
CVS Caremark formulary proposal in final stages; target July 1, 2026; gross-to-net target ~50%.
Sales force expanded to 148 reps; SG&A $72.2M includes DTC marketing investment.
Health Canada approved neffy on April 15; EU 1 mg dose approved for children 4+ years.
Phase 2b CSU trial interim population fully enrolled; data expected Q4 2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ARS Pharmaceuticals, Inc. reported first quarter of 2026 results: revenue $22.7 million, net income ($60.6 million), EPS ($0.61) per share basic and diluted.

Period: first quarter of 2026
Revenue: $22.7 million
Net income: ($60.6 million)
EPS: ($0.61) per share basic and diluted
Result: reported results

Exact text from the filing

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update Q1 2026 total revenue of $22.7 million

View on SEC.gov

Browse all earnings releases →

ARS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-225055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.